Holen Sie sich die Stockscreener-App
23.67
5.15%
1.16
Schlusskurs vom Vortag:
$22.51
Offen:
$22.75
24-Stunden-Volumen:
6.39M
Relative Volume:
0.98
Marktkapitalisierung:
$11.83B
Einnahmen:
$4.89B
Nettoeinkommen (Verlust:
$-242.00M
KGV:
-48.40
EPS:
-0.489
Netto-Cashflow:
$315.00M
1W Leistung:
+7.01%
1M Leistung:
-7.36%
6M Leistung:
-5.81%
1J Leistung:
+31.50%
1-Tages-Spanne:
$22.67
$23.69
1-Wochen-Bereich:
$21.32
$23.69
52-Wochen-Spanne:
$17.11
$27.98
Elanco Animal Health Inc Stock (ELAN) Company Profile
Firmenname
Elanco Animal Health Inc
Sektor
Telefon
877-352-6261
Adresse
450 ELANCO CIRCLE, INDIANAPOLIS
Compare ELAN vs TAK, TEVA, HLN, ZTS, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ELAN
Elanco Animal Health Inc
|
23.67 | 11.06B | 4.89B | -242.00M | 315.00M | -0.489 |
TAK
Takeda Pharmaceutical Co Adr
|
17.63 | 55.60B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
36.77 | 42.81B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.70 | 43.16B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
73.79 | 30.39B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
499.73 | 21.95B | 3.17B | 1.29B | 1.01B | 27.09 |
Elanco Animal Health Inc Stock (ELAN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-15 | Eingeleitet | Citigroup | Buy |
| 2026-01-22 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2025-12-09 | Eingeleitet | Barclays | Overweight |
| 2025-11-21 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2025-11-19 | Hochstufung | Argus | Hold → Buy |
| 2025-10-07 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2025-07-17 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-06-26 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2024-12-09 | Eingeleitet | UBS | Buy |
| 2024-12-02 | Eingeleitet | Leerink Partners | Market Perform |
| 2024-09-19 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-01-05 | Hochstufung | Stifel | Hold → Buy |
| 2023-12-19 | Eingeleitet | Jefferies | Buy |
| 2023-12-15 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2023-12-07 | Eingeleitet | Exane BNP Paribas | Outperform |
| 2023-04-20 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2022-08-18 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-08-16 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2022-07-21 | Herabstufung | Goldman | Buy → Sell |
| 2022-07-12 | Eingeleitet | Piper Sandler | Neutral |
| 2021-11-18 | Eingeleitet | Morgan Stanley | Overweight |
| 2021-10-28 | Herabstufung | Stifel | Buy → Hold |
| 2021-08-05 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-06-15 | Hochstufung | Cleveland Research | Underperform → Neutral |
| 2021-05-11 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2021-05-11 | Hochstufung | Gabelli & Co | Hold → Buy |
| 2021-04-15 | Eingeleitet | Stifel | Buy |
| 2021-03-22 | Herabstufung | Gabelli & Co | Buy → Hold |
| 2021-02-26 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2020-12-09 | Herabstufung | Argus | Buy → Hold |
| 2020-11-09 | Herabstufung | Barclays | Overweight → Underweight |
| 2020-08-20 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-08-13 | Fortgesetzt | Credit Suisse | Neutral |
| 2020-08-04 | Fortgesetzt | Goldman | Buy |
| 2020-07-27 | Herabstufung | Cleveland Research | Neutral → Underperform |
| 2020-04-02 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-01-10 | Eingeleitet | Raymond James | Mkt Perform |
| 2019-12-19 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2019-11-07 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2019-09-23 | Eingeleitet | Barclays | Overweight |
| 2019-08-26 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2019-08-15 | Hochstufung | UBS | Sell → Neutral |
| 2019-05-23 | Eingeleitet | Guggenheim | Neutral |
| 2019-03-18 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2019-03-13 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2019-02-12 | Eingeleitet | William Blair | Mkt Perform |
| 2019-01-23 | Eingeleitet | UBS | Sell |
| 2019-01-15 | Eingeleitet | Argus | Buy |
| 2018-10-15 | Eingeleitet | Morgan Stanley | Equal-Weight |
Alle ansehen
Elanco Animal Health Inc Aktie (ELAN) Neueste Nachrichten
S&CO Inc. Buys Shares of 111,284 Elanco Animal Health Incorporated $ELAN - marketbeat.com
7th Circ. Won't Revive Elanco Investors' Securities Fraud Suit - Law360
Is Elanco Animal Health Inc (ELAN) Overvalued After 5.2% Rally? - GuruFocus
Elanco Investors Fail to Revive Sales Misrepresentation Suit (2) - Bloomberg Law News
5 Must-Read Analyst Questions From Elanco’s Q2 Earnings Call - Yahoo Finance
Elanco Animal Health (NYSE:ELAN) Director Buys 5,000 Shares - marketbeat.com
Elanco Animal Health (ELAN) director purchases 5,000 shares of stock - Stock Titan
Elanco rating upgraded by Fitch on deleveraging progress - Investing.com Canada
Analysts Offer Insights on Healthcare Companies: Elanco Animal Health (ELAN) and ACADIA Pharmaceuticals (ACAD) - The Globe and Mail
Elanco Animal Health expands US screwworm response - foxbusiness.com
Elanco (ELAN): Innovation Is Turning A Leveraged Portfolio Into A Share-Taking Platform - Seeking Alpha
Elanco Animal Health Incorporated (ELAN) Stock Price, News, Quote & History - Yahoo! Finance Canada
Elanco Animal Health (ELAN) Insider Buying: EVP and CFO Robert V - GuruFocus
Elanco receives FDA emergency authorization for screwworm spray - Investing.com
Elanco's CLiK(TM) Extra (Dicyclanil Topical Suspension) Wound Spray Receives FDA Emergency Use Authorization for Application on or Around Wounds for Prevention of New World Screwworm in Variety of Livestock and Captive and Captured Wildlife Speci - ACCESS Newswire
Insider Buying: Elanco Animal Health (NYSE:ELAN) CFO Buys $96,936.00 in Stock - marketbeat.com
Insider Buying: Elanco Animal Health (NYSE:ELAN) Director Buys 10,000 Shares of Stock - marketbeat.com
ELAN Stock Jumps As Earnings Beat Fuels Bullish Guidance - StocksToTrade
Elanco Animal Health (NYSE: ELAN) EVP granted new deferred stock units - Stock Titan
Elanco (ELAN) CFO boosts stake with 4,200-share buy and new Deferred Stock Units - Stock Titan
Elanco (ELAN) CEO Jeffrey Simmons receives new deferred stock unit grant - Stock Titan
Elanco Animal Health (NYSE: ELAN) director buys 10,000 shares at $23.69 - Stock Titan
Bank of America Corp DE Has $80.36 Million Stake in Elanco Animal Health Incorporated $ELAN - marketbeat.com
Does Elanco (ELAN) Have a Durable Edge in Animal Health After Its Screwworm EUA Win? - Yahoo! Finance Canada
Elanco Animal Health (ELAN) Following FDA Emergency Use Authorization Has Valuation Back In Focus - Yahoo Finance
INVESTOR ALERT AND NOTICE: Kaskela Law Firm Announces Investigati - The National Law Review
Elanco Animal Health Incorporated (NYSE:ELAN) Receives Average Recommendation of "Moderate Buy" from Brokerages - marketbeat.com
Elanco Animal Health Q2 Earnings Call Highlights - MarketBeat
elanco animal health inc. Positive Earnings Pre-Announcements - RTTNews
ELAN Looks 42.8% Overvalued on GF Value™ - GuruFocus
Elanco Animal Health Inc (ELAN) Shares Fall 8.6% -- GF Value Says Still Overvalued - GuruFocus
Elanco Animal Health Incorporat (ELAN) Stock forecasts - Yahoo Finance UK
ELAN Looks 35.7% Overvalued on GF Value™ as Market Prices in Fut - GuruFocus
Elanco wound spray can help protect livestock from screwworm - stocktitan.net
Elanco Animal Health (NYSE:ELAN) Sees Unusually-High Trading Volume on Analyst Upgrade - MarketBeat
Elanco Ends Lobbying Relationship With Stumptown Strategies - Legis1
Amundi Has $2.35 Million Stock Holdings in Elanco Animal Health Incorporated $ELAN - MarketBeat
Cetera Investment Advisers Buys 65,526 Shares of Elanco Animal Health Incorporated $ELAN - marketbeat.com
UBS Adjusts Price Target on Elanco Animal Health to $33 From $31, Maintains Buy Rating - Moomoo
Elanco Animal Health Inc (ELAN) Shares Fall 7.7% -- What GF Scor - GuruFocus
Elanco CEO on Boosted Forecast, Surge in Tick Bites - Yahoo Finance
Elanco raises 2026 outlook after strong second-quarter results - Feed Strategy
UBS Group Boosts Elanco Animal Health (NYSE:ELAN) Price Target to $33.00 - marketbeat.com
Why Elanco Animal Health (ELAN) Stock Is Down Today - Quiver Quantitative
Elanco Animal Health (NYSE:ELAN) Stock Price Expected to Rise, KeyCorp Analyst Says - MarketBeat
Elanco Animal Health Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
Elanco Animal Health (ELAN) Stock Eyes Margin Momentum As Debt Questions Linger - simplywall.st
Elanco Animal Health Incorporat (ELAN) Stock Forecasts - Yahoo! Finance Canada
Elanco Earnings: Continued Strength in Key New Products Supports Strong Quarter - Morningstar
Elanco Animal Health CEO Jeff Simmons goes one-on-one with Jim Cramer - cnbc.com
Elanco Animal Health Inc (ELAN) (Q2 2026) Earnings Call Highligh - GuruFocus
Finanzdaten der Elanco Animal Health Inc-Aktie (ELAN)
Umsatz
Nettogewinn
Free Cashflow
ENV
Elanco Animal Health Inc-Aktie (ELAN) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| VanHimbergen Robert M | EVP and CFO |
Aug 07 '26 |
Buy |
23.08 |
4,200 |
96,926 |
137,516 |
| Herendeen Paul | Director |
Aug 07 '26 |
Buy |
23.68 |
10,000 |
236,850 |
111,687 |
| Modi Rajeev A. | SEE REMARKS |
May 15 '26 |
Buy |
20.35 |
4,911 |
99,939 |
160,812 |
| Simmons Jeffrey N | PRESIDENT, CEO AND DIRECTOR |
May 15 '26 |
Buy |
20.09 |
4,971 |
99,843 |
171,971 |
| Kurzius Lawrence Erik | Director |
Dec 12 '25 |
Buy |
21.30 |
10,000 |
213,000 |
131,773 |
| Modi Rajeev A. | SEE REMARKS |
Dec 11 '25 |
Buy |
21.33 |
4,500 |
95,985 |
123,082 |
| VanHimbergen Robert M | EVP and CFO |
Dec 11 '25 |
Buy |
21.64 |
6,950 |
150,426 |
124,233 |
| Simmons Jeffrey N | PRESIDENT, CEO AND DIRECTOR |
Dec 11 '25 |
Buy |
21.75 |
22,000 |
478,496 |
167,000 |
1.21%
1.26%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):